ARCHIVES

Early ADT Doesn’t Offer Survival Advantage—ASCO

This article is from The Cancer Letter archive.

Vol. 30 No. 4 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

February 15, 2002

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

Barret’s Less of a Risk Factor For Cancer of the Esophagus

June 24, 2011

NCI To Fund Two Construction Grants With 42 Million From Special NIH Fund

March 2, 1990

CT Scanning Use, Costs, Controls Debated By NCAB

October 7, 1977

In Brief: Fred Hutchinson Center celebrates Massive Move Of 36 Labs, 400 Employees to New Campus

June 25, 1993